CLINICAL TRIALS PROFILE FOR DIMETHYL SULFOXIDE

Clinical Trials for Dimethyl Sulfoxide

Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

Completed

National Cancer Institute (NCI)

Phase 1

RATIONALE: Vaccines made from peptides may help the body build an effective immune response
to kill tumor cells. Biological therapies, such as imiquimod, may stimulate the immune
system in different ways and stop tumor cells from growing. Giving vaccine therapy together
with imiquimod after surgery may help the body kill any remaining tumor cells.
PURPOSE: This randomized phase I trial is studying the side effects and best way to give
vaccine therapy with or without imiquimod in treating patients who have undergone surgery
for stage II, stage III, or stage IV melanoma.

Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

Completed

Craig L Slingluff, Jr

Phase 1

RATIONALE: Vaccines made from peptides may help the body build an effective immune response
to kill tumor cells. Biological therapies, such as imiquimod, may stimulate the immune
system in different ways and stop tumor cells from growing. Giving vaccine therapy together
with imiquimod after surgery may help the body kill any remaining tumor cells.
PURPOSE: This randomized phase I trial is studying the side effects and best way to give
vaccine therapy with or without imiquimod in treating patients who have undergone surgery
for stage II, stage III, or stage IV melanoma.

The primary objective of this study is to evaluate the efficacy and tolerability of the
intravesical cocktail and its comparison with intravesical DMSO in a controlled trial for
the treatment of painful bladder syndrome including interstitial cystitis.

The aim of this study is to visualize the tumor hypoxic tissue, the potential quantitative
changes and the biological behavior of cervical carcinoma (primary and / or lymph nodes)
before, during and after radiochemotherapy with the novel hypoxia PET tracer 18FAZA.

The primary objective of this pilot study is to evaluate the safety and efficacy of direct
instillations of Botulinum-A toxin/DMSO into the bladder via a catheter system as a means of
treating women with symptoms of overactive bladder and secondary urinary incontinence. In
doing so, we will focus on estimating the percentage of women who experience an improvement
in their urinary incontinence symptoms at one month and three months following this novel
instillation technique.

Trial ID

Title

Status

Sponsor

Phase

Summary

This preview shows a limited data set.Subscribe to access the full database, or try a Free Trial

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.